◆ TICKERBASEVista interattiva →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › Tutte le azioni › EMCURE · English version

Emcure Pharmaceuticals Limited (EMCURE)

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-11-02

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine.

Dati chiave

Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →

Conto economico annuale

Conto economicoTTM → 2026-06-302026-03-312025-03-312024-03-312023-03-312022-03-31
Entrate totali₹96.8B₹91.2B₹78.1B₹65.8B₹59.3B—
Utile lordo₹57.6B₹52.2B₹44.9B₹39.7B₹35.2B—
Risultato Operativo (EBIT)₹14.7B₹13.7B₹10.8B₹9.2B₹9.4B—
Reddito netto₹10.1B₹9.2B₹6.8B₹5.0B₹5.3B—

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di EMCURE. /companies/us/EMCURE

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.